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Abstract  
 
Objective. Plant-derived alpha-linolenic acid (ALA) may constitute an attractive 
cardioprotective alternative to fish-derived n-3 fatty acids. However, the effect of 
dietary ALA on arterial thrombus formation remains unknown. 
Methods and Results.  Male C57Bl/6 mice were fed a high ALA or low ALA diet for 
2 weeks. Arterial thrombus formation was delayed in mice fed a high ALA diet as 
compared to those on a low ALA diet (n=7; p<0.005). Dietary ALA impaired platelet 
aggregation to collagen and thrombin (n=5; p<0.005) and decreased p38 MAP 
kinase activation in platelets. Dietary ALA impaired arterial tissue factor (TF) 
expression, TF activity and NFκB activity (n=7; p<0.05); plasma clotting times and 
plasma thrombin generation did not differ (n=5; p=NS). In cultured human vascular 
smooth muscle and endothelial cells ALA inhibited TF expression and activity (n=4; 
p<0.01). Inhibition of TF expression occurred at the transcriptional level via the MAP 
kinase p38 in smooth muscle cells and p38, ERK1/2, and JNK1/2 in endothelial cells. 
Conclusions. ALA impairs arterial thrombus formation, TF expression, and platelet 
activation, and thereby represents an attractive nutritional intervention with direct 
dual anti-thrombotic effects. 
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Arterial thrombosis is the critical step in the development of acute vascular 
syndromes.1,2,3 Circulating platelets are activated by interaction with subendothelial 
collagen at the site of an injury.4 In parallel, membrane bound tissue factor (TF) 
expressed on vascular cells acts as a receptor for activated factor VII (VIIa).5,6 The 
TF/VIIa complex triggers the coagulation cascade and the formation of activated 
factor X (Xa) ultimately resulting in thrombin formation, which in turn cleaves 
protease-activated receptors on the platelet surface boosting platelet activation and 
clot formation4. The critical role of platelets and TF in the pathogenesis of acute 
coronary syndromes has indeed been well documented.7,8,9  
Experimental and epidemiological studies have extensively characterized the 
cardioprotective and anti-thrombotic effects of fish-derived dietary long chain n-3 fatty 
acids eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-
3, DHA).10,11,12,13 Consistent with these observations, an increased risk for developing 
cardiovascular disease was identified in populations with low intake of EPA and DHA, 
prompting the American Heart Association (AHA) to modify their nutrition 
guidelines.14  
ALA is an essential n-3 FA found at high concentrations in vegetable oils, in 
particular flaxseed oil, where it accounts for 50% of the total FA content. Following 
oral intake, ALA is partially converted into EPA and DHA. The rate of conversion of 
ALA into long chain n-3 fatty acids ranges from 0.05 to 10%.15 In recent 
epidemiological studies, ALA consumption has been inversely associated with the 
incidence of myocardial infarction, sudden cardiac death, and coronary artery 
calcification.16-20 Despite these promising data, the precise biological mechanisms 
mediating the cardioprotective effects of ALA remain barely understood. In particular, 
it remains controversial whether the rather poor conversion of ALA to EPA and DHA 
can account for the beneficial effects of ALA or whether ALA exerts direct biological 
effects.21,22  
Since increasing evidence suggests that ALA can serve as a cardioprotective 
nutritional supplement, this study addresses the question whether dietary ALA 
inhibits thrombus formation in vivo and analyzes the mechanisms involved. 
 
 
Materials and Methods 
 
For the detailed Materials and Methods please see the supplemental Materials and 
Methods (available online at http://atvb.ahajournals. org). 
 
ALA diet and carotid artery thrombosis model  
C57BL/6 mice were fed a 0.21% w/w cholesterol diet containing either a high 
ALA (7.3%) or low ALA concentration (0.03%, supplemental table 1).23 
Photochemical injury model was performed after 2 weeks of treatment. 
 
Immunohistochemistry 
Thrombus composition was analysed in paraffin fixed sections from occluded 
carotid arteries. Sections were stained for TF, fibrin, and the platelet marker CD41. 
 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
Plasma was isolated from citrated blood (3.2%; 1/10) by centrifugation (2500g; 
4°C; 15 minutes). PT and aPTT were assessed using the START 4 analyzer 
(Diagnostica Stago, France). 24 
   
Thrombin generation 
Plasma thrombin generation was monitored by automated calibrated 
thrombography and the results analysed using the Thrombinoscope software 
(Thrombinoscope BV, Maastricht, The Netherlands).25,26  
 
Platelet aggregation 
Platelet aggregation was studied by whole blood impedance aggregometry 
(Chrono-Log, Havertown, PA, USA).  
 
Fatty acid profile in aortic tissue 
FA profiles of the pooled tissues were analyzed by gas chromatography as 
described.27 Measurements were performed in duplicate and the mean value 
displayed.  
 
Cell culture 
 Human aortic vascular smooth muscle cells (VSMC; Clonetics, Allschwil, 
Switzerland) and human aortic endothelial cells (HAEC; Clonetics) were cultured as 
described.24 Protein expression was determined by Western blot analysis and RNA 
by real-time polymerase chain reaction (PCR). 
 
Tissue factor activity  
Factor Xa generation on the surface of VSMC, HAEC, or in tissues was 
analyzed using a colorimetric assay (American Diagnostica Inc, ACTICHROME).  
 
TF promoter activity 
TF promoter activity was measured as described.28 A minimal TF promoter (-
227 bp to +121 bp) was cloned upstream of the firefly luciferase reporter gene and a 
recombinant adenoviral vector was constructed. HAEC were transduced with the 
vector Ad5/hTF/Luc (100 pfu/cell) for 1 hour. An adenoviral vector without reporter 
gene (VQAd/Empty) was used as a negative control. After transduction, HAEC were 
grown in medium (10% FBS) for 24 hours and then serum-starved for 24 hours prior 
to TNF-α stimulation with or without ALA (30 µM) pretreatment. Firefly luciferase 
activity was determined by luminometer (Berthold Technologies, Bad Wildbad, 
Germany) and normalized to the protein concentration in the lysates. 
 
Nuclear extracts and NFkB activity  
Nuclear extracts were obtained from HAEC or mouse aorta using a nuclear 
extraction kit (Active Motif, Carlsbad, USA) and NFκB activity measured using a 
TransAM NFκB p65 kit (Active Motif). 
 
Statistics 
Data are presented as mean±SEM. Statistics were performed using the 
GraphPad prism 4.0 Software (GraphPad Software Inc., La Jolla, CA, USA). 
Statistical analysis was performed using 2-tailed unpaired Student´s t-test or one-way 
ANOVA as appropriate. A value of p<0.05 was considered significant.  
Results 
 
Dietary ALA inhibits arterial thrombosis 
C57BL/6 mice were fed for 2 weeks a 0.21% cholesterol diet containing either 7.3% 
w/w ALA (high ALA, treated group) or 0.03% w/w ALA (low ALA, control group). No 
difference in body weight was observed after 2 weeks of diet (n=7; p=NS; data not 
shown). Aorta from animals fed a high ALA diet showed markedly increased ALA 
levels (14.9% of total FA content; supplemental table 2) as compared to tissue from 
control animals (0.14% of total FA content; supplemental table 2). In contrast, EPA 
and DHA levels did not differ between the two groups. Total cholesterol levels were 
not altered (control: 2.27±0.17 mmol/l; low ALA: 1.95±0.21 mmol/l; high ALA: 
2.29±0.30 mmol/l; n=8; p=NS). 
Mice on control diet developed carotid artery thrombosis within a mean occlusion 
time of 40±4.2 minutes, while mice on high ALA diet occluded after 68±6 minutes 
(n=7; p<0.005; figure 1A). Initial blood flow did not differ between the two groups 
(n=7; p=NS). Intravenous administration of an inhibitory anti-TF antibody before the 
onset of photochemical injury reduced the difference in occlusion times between 
control and high ALA diet (n≥7; p=NS; figure 1B). Plasma clotting times (PT and 
aPTT) were similar in the two groups (PT: 11.1±0.2 seconds [low ALA] versus 
11.5±0.4 seconds [high ALA]; n=7; p=NS; aPTT: 20.3±0.8 seconds [low ALA] versus 
21.1±0.7 seconds [high ALA]; n=7; p=NS). Thrombin generation (endogenous 
thrombin potential [ETP] and time to peak [TTP]) did not differ between the groups 
(ETP: 747±94 nM/minute [low ALA] versus 818±80 nM/minute [high ALA]; n=5; 
p=NS; TTP: 6.2±0.7 minutes [low ALA] versus 4.8±0.5 minutes [high ALA]; n=5; 
p=NS). Further no difference in peak thrombin values (104.4±28.7 nM [low ALA] 
versus 118.8±22.9 nM [high ALA]; n=5; p=NS) nor in lag times (2.9±1.36 minutes 
[low ALA] versus 2.1±1.3 minutes [high ALA]; n=5; p=NS) was observed between the 
groups.  
To analyse differences in thrombus composition, sections from occluded 
carotid arteries were stained for TF, fibrin, and platelets. Although thrombi were 
occlusive in both groups, TF staining of in the vascular media was lower in the high 
ALA group as compared to the control group (figure 1C; n=4). In contrast, fibrin 
staining was similar in thrombi from both groups. Analysis of platelet content by 
immunhistochemistry for CD41 demonstrated a reduced platelet content in thrombi in 
the ALA treated group as compared to control (figure 1D; n=4). 
 
Dietary ALA inhibits platelet aggregation  
Thrombin induced platelet aggregation (figure 2A-D) was inhibited in mice fed 
a high ALA diet as compared to control platelets (maximal aggregation: n=5, 
p<0.005, figure 2B; area under the curve: n=5; p<0.005, figure 2C; lag time: n=5, 
p<0.05, figure 2D). When aggregation was induced by collagen, a similar inhibition 
was observed (maximal aggregation: n=5, p<0.005, figure 2F; area under the curve: 
n=5, p<0.05, figure 2G; lag time: n=5, p=0.14, figure 2H). Platelet number did not 
differ significantly between the groups (1062±46x103/μL [low ALA] versus 
911±5x103/μL [high ALA]; n=5; p=NS). 
Treatment of human platelets with ALA (30 μM) for 30 minutes ex vivo exerted 
a similar inhibition of thrombin and collagen induced platelet aggregation (n=5; 
supplemental table 3A-B). ALA (30 μM) impaired collagen and thrombin induced p38 
phosphorylation (n=3; p<0.01 versus collagen or thrombin alone; supplemental figure 
1A-B). 
 
Dietary ALA inhibits TF expression and NFκB activation 
TF activity in carotid arteries was markedly decreased in mice fed a high ALA 
diet as compared to controls (n=7; p<0.005, figure 3A). Inhibition of TF with a specific 
antibody confirmed that factor Xa generation was TF dependent (figure 3B). This 
decrease in TF activity was paralleled by an impaired TF mRNA expression in aortic 
tissue (n=7; p<0.01; figure 3C). In contrast, expression of tissue factor pathway 
inhibitor (TFPI) mRNA did not differ (ΔΔCt: 0.03±0.04 low ALA group versus 
0.03±0.04 high ALA; n=5; p=NS). NFκB p65 DNA binding affinity was measured in 
nuclear extracts from aortic tissue. NFκB activity was impaired in mice fed a high 
ALA diet as compared to controls (OD 490 nm: 0.97±0.02 [low ALA] versus 
0.70±0.09 [high ALA]; n=7; p<0.05, figure 3D). 
 
ALA inhibits TF protein expression in VSMC 
Treatment with ALA (30 μM) for 24 hours reduced TF expression in VSMC by 
46% (n=4; p<0.05) as compared to control (figure 4A). Real time PCR analysis 
confirmed that ALA inhibited TF expression in VSMC at the transcriptional level (n=4; 
p<0.005; figure 4B). In line with this observation, ALA decreased TF activity in VSMC 
(n=4; p<0.001; figure 4C). Experiments performed with an inhibitory anti-TF antibody 
confirmed that factor Xa generation in VSMC was TF dependent (figure 4D). TF 
expression was neither affected by the n-6 FA alpha-linoleic acid (LA) nor the 
saturated FA stearic acid (SA) (n=4; p=NS; data not shown). No cytotoxic effects of 
ALA, LA, or SA in VSMC were observed for any of the concentrations (data not 
shown).  
 
ALA inhibits p38 phosphorylation and NFkB activity in VSMC 
Analysis of the MAP kinase phosphorylation demonstrated that treatment of 
VSMC with ALA for 24 hours resulted in a significant decrease in p38 activation 
(49±14% inhibition; n=4; p<0.05; figure 5A). In contrast, activation of JNK and ERK 
remained unaffected. Blockade of the MAP kinase p38 with SB203580 (10 μM)  
inhibited TF expression in VSMC (n=4; p<0.01; figure 5B). Treatment with ALA (30 
μM) reduced NFκB p65 DNA binding affinity in nuclear extracts from VSMC (n=4; 
p<0.05; figure 5C). 
 
ALA inhibits TNF-α induced TF mRNA expression via MAP kinase and 
ASK1 in HAEC 
HAEC were treated with ALA or vehicle for 1 hour and then stimulated with 
TNF-α (5 ng/mL) for 4 hours. ALA inhibited TNF-α induced endothelial TF expression 
in a concentration dependent manner with a maximal effect at 30 μM (86% inhibition; 
n=5; p<0.001 versus TNF-α alone; figure 6A). In line with this observation, ALA 
decreased TF activity in HAEC (51% inhibition versus TNF-α alone; n=4; p<0.001; 
figure 6B).  
Real-time PCR analysis demonstrated that ALA (30 μM) inhibited TNF-α 
induced endothelial TF mRNA expression (n=4; p<0.001; Figure 6C). This decrease 
in TF mRNA was paralleled by an impaired activation of the MAP kinases JNK, p38, 
and ERK (28%, 62%, and 55% inhibition versus TNF-α alone, respectively; n=4; 
p<0.05; figure 6D). Consistent with this pattern of MAP kinase inhibition, ALA 
impaired activity of the MAPKKK ASK1 (n=3; p<0.005 versus TNF-α alone; figure 
6E). ALA (30 μM) inhibited TNF-α induced TF promoter activation in HAEC by 47% 
(n=4; p<0.05, figure 6F). ALA (30 μM) blunted TNF-α induced IκB-α degradation 
(n=3; p<0.05). This effect was paralleled by reduced DNA binding activity of the 
NFκB subunit p65 (54% inhibition versus TNF-α alone, n=4; p<0.01). To confirm the 
involvement of NFκB in TNF-α induced endothelial TF expression, the effect of 
different NFκB inhibitors was assessed. Both BAY 11-7082 (5 μM) and PDTC (10 
μM) inhibited TNF-α induced TF expression (-66% and -47% versus TNF-α alone, 
respectively; n=4; p<0.01). 
 
Discussion 
 
Variations of the dietary n-3/n-6 ratio have been reported to affect the 
susceptibility to thrombosis in atherosclerotic mice.29 However, it remains unknown 
whether ALA can exert such an effect and whether if influence thrombosis directly or 
via other PUFA. 
The present study demonstrates that dietary supplementation with ALA for 2 
weeks impaired arterial thrombus formation, platelet activation, TF activity, and NFκB 
activity in mice in vivo. The ALA rich diet increased tissue levels of ALA, while there 
was no significant change in tissue levels of the long chain n-3 FA EPA and DHA. 
Consistent with these findings, ALA by itself impaired platelet aggregation and TF 
induction in different human primary cells cultures. This effect occurred at the 
transcriptional level involving inhibition of MAP kinase phosphorylation, NFκB 
activation, and promoter activation.  
The ALA concentrations used for experiments in this study are in a clinically 
relevant range. Indeed, baseline plasma levels of ALA have been reported to range 
from 17-19 μM, whereas a daily oral ingestion of 3 g ALA leads to ALA plasma levels 
of 32±17 μM and is well tolerated15. Dietary supplementation of ALA for 2 weeks was 
sufficient to markedly increase the ALA levels in the aortic wall, whereas EPA and 
DHA levels did not differ from the control group. The lack of a measurable conversion 
to long chain n-3 FA is in line with previous epidemiological studies demonstrating 
that dietary ALA poorly correlates with EPA and DHA levels in adipose tissue, 
erythrocytes or plasma16. Even more important, the in vivo effects of dietary ALA 
observed in the present study were mimicked by exogenous ALA in both human 
platelets and vascular cells ex vivo, where hepatic conversion of ALA to EPA and 
DHA does not occur. Taken together, these experiments indicate that the anti-
thrombotic effects of ALA in vivo did not depend on the conversion of ALA to long 
chain n-3 FA and provide strong evidence for a direct biological effect of ALA.  
To exclude possible effects of other FA, control experiments were performed 
with the n-6 FA linoleic acid as well as the saturated FA stearic acid. Neither of these 
FA altered TF expression, supporting the interpretation that the biological effects of 
the high ALA diet on TF and thrombosis occur due to the increased ALA levels. 
 Dietary ALA supplementation significantly delayed arterial thrombus formation 
triggered by photochemical injury in vivo. Since this effect was paralleled by a 
reduced platelet activation and a diminished arterial TF activity, ALA impairs 
thrombus formation by a dual action on both critical events involved in arterial 
thrombosis following vascular injury. In order to determine the relative contribution of 
platelets and TF to thrombus formation, an inhibitory anti-TF antibody was applied. 
Treatment with this antibody reduced the difference in occlusion times between the 
two groups, suggesting that the inhibitory effect of ALA on TF exerts a major effect 
on thrombus formation, while its effect on pletelets contributes to inhibition of 
thrombosis. These results support previous observations demonstrating that arterial 
thrombosis is primarly driven by TF derived from the vessel wall in this model.30,31 TF 
is barely expressed under basal conditions in endothelial cells, while it is 
constitutively expressed in VSMC.32 Immunohistochemical analysis confirmed that TF 
expression in the arterial tunica media was decreased in carotid arteries derived from 
the ALA treated group. Inhibition of TF was confirmed in vivo, since the ALA rich diet 
decreased TF expression and NFkB activity in arterial lysates. Consistent with these 
in vivo observation, treatment of VSMC with ALA for 24 hours decreased basal TF 
expression. This effect was mediated at the transcriptional level via the MAP kinase 
p38. Pharmacological inhibition of p38 confirmed the crucial role of p38 activation in 
constitutive TF expression in VSMC. In line with p38 inhibition as well as with 
previous data obtained in monocytes and macrophages ALA also reduced  NFkB 
activity in VSMC.33,34 Hence, direct inhibition of TF in VSMC via p38 and NFkB 
seems to play a major role in ALA’s effect on arterial thrombus formation. 
In order to study whether ALA also affects inducible TF expression, additional 
experiments were performed in cytokine activated endothelial cells. TNF-α induced 
endothelial TF expression is mediated through activation of MAP kinases leading to 
activation of transcription factors such as AP-1 and EGR-1, whereas the IκB kinase 
pathway promotes NFκB activation.35,36 ASK1 is a redox regulated kinase playing an 
essential role in stress induced activation of MAP kinases, thus triggering various 
cellular processes including inflammatory responses and TF expression.32,37 In 
endothelial cells, TNF-α has been shown to activate ASK1 as well as MAP 
kinases.6,37 Treatment with ALA significantly reduced phosphorylation of the MAP 
kinases p38, JNK, and ERK in endothelial cells. Consistent with the inhibition of MAP 
kinase phosphorylation, ALA also prevented activation of ASK1. Thus, it is likely that 
ASK1 represents a common upstream target of ALA disrupting the MAP kinase 
signalling pathway in endothelial cells. 
Immunohistochemical analysis of CD41 (platelet glycoprotein IIb) expression 
demonstrated that thrombi contained less platelets in the ALA treated group as 
compared to the control group. Platelet aggregation was analyzed using collagen and 
thrombin as agonists, since they play a dominant role in platelet activation following 
vascular injury.3 ALA impaired both collagen and thrombin induced platelet 
aggregation, indicating that ALA inhibits glycoprotein VI and Ib-V-IX as well as 
protease-activated receptor mediated platelet activation; hence, ALA does not 
interfere with activation of a single pathway. Since the MAP kinase p38 plays a 
crucial role in collagen as well as thrombin induced platelet activation and adhesion, 
the effect of ALA on p38 phosphorylation in isolated platelets was investigated.38,39 
ALA decreased collagen and thrombin induced p38 activation, an effect that may well 
account for the reduced aggregation observed in ALA treated platelets. Taken 
together, these observations may provide an explanation for the remaining difference 
in occlusion times observed between the two groups after treatment with an inhibitory 
anti-TF antibody. 
In summary, this study provides solid evidence for a potent dual anti-
thrombotic effect of an ALA rich diet by reducing platelet activation and impairing 
vascular TF expression. These effects were reproduced in a mouse model as well as 
in human primary cell cultures and were not related to an increase in EPA and DHA 
levels as confirmed by our data. Hence, this study generates pathophysiological 
evidence for direct anti-thrombotic effects of dietary ALA supplementation. Since the 
limited availability or unfavourable geographic conditions restrict the access to n-3 FA 
from marine origin in many countries, plant-derived ALA might therefore represent an 
attractive cardioprotective alternative. However, keeping in mind previous clinical 
setbacks with experimentally promising nutritional compounds such as vitamin E, 
there is a great need for placebo-controlled randomized large-scale clinical trials to 
confirm the long-term anti-thrombotic potential of dietary supplemented ALA. 
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 Figure Legends 
 
Figure 1. Dietary ALA inhibits arterial thrombus formation.  
A. Dietary ALA impairs time to thrombotic occlusion after photochemical injury in the 
mouse carotid artery in vivo (*p<0.005). B. Treatment with an inhibitory anti-TF 
antibody blunts the difference in occlusion times (p=NS). C. Sections of thrombosed 
carotid artery (L: vessel lumen, M: vessel media) from control and ALA treated 
animals (n=4) were stained for TF and fibrin (brown stain). Scale bars equal 50 μm; 
HE: hematoxylin and eosin stain. D. Sections from occluded carotid arteries were 
also stained for CD41 (red stain) and nuclei (blue stain). Scale bars equal 100 μm. 
HE: hematoxylin and eosin stain. 
 
Figure 2. Dietary ALA inhibits platelet aggregation. 
Thrombin (A) and collagen (E) induced platelet activation is inhibited in mice fed a 
high ALA diet as compared to control animals. Dietary ALA reduced maximal 
aggregation (B. thrombin: *p<0.005; F. collagen: *p<0.005), reduced area under the 
curve (C. thrombin: *p<0.005; G. collagen: *p<0.05), and increased lag time (D. 
thrombin: *p<0.05; H. collagen: p=NS). 
 
Figure 3. Dietary ALA inhibits TF expression and NFκB activity in vivo. 
Dietary ALA inhibits TF activity as assessed by FXa generation in carotid arteries (A. 
*p<0.005). B. Treatment of tissue lysates with an inhibitory anti-TF antibody (10 
mg/ml) inhibits FXa generation (*p<0.01 versus control diet group in the presence of 
an IgG control antibody). Dietary ALA impairs TF mRNA expression (C. *p<0.05), 
and NFkB p65 DNA binding affinity (D. *p<0.05) in mouse carotid arteries.  
 
Figure 4. ALA inhibits TF expression in VSMC. 
A. Treatment with ALA (30 μM) for 24h inhibits TF protein expression in VSMC 
(*p<0.05 versus control). B. ALA (30 μM) inhibits TF mRNA expression (*p<0.005 
versus control) after 24h. C. ALA (30 μM) also impairs TF activity in VSMC 
(*p<0.001). D. Treatment of VSMC with an inhibitory anti-TF antibody inhibits FXa 
generation (*p<0.05 versus control treated with an IgG control antibody).  
 
Figure 5. ALA inhibits p38 activation and NFkB activity in VSMC. 
A. Treatment with ALA (30 μM) for 24h decreases p38 activation in VSMC  (*p<0.05 
versus control). B. Inhibition of p38 with SB203580 (10 μM) for 24h impairs TF 
expression in VSMC (*p<0.01 versus control). C. ALA (30 μM) reduces DNA binding 
activity of the NFκB subunit p65 in VSMC (*p<0.05 versus control). 
 
Figure 6. ALA inhibits TNF-α induced TF expression in HAEC 
A. Treatment with ALA (10-30 μM) for 1h inhibits TNF-α induced TF protein 
expression in human endothelial cells (*p<0.01 versus TNF-α alone). B. ALA  (30 
μM) inhibits TNF-α induced endothelial TF surface activity (*p<0.001 versus TNF-α 
alone). C. ALA (30 μM) inhibits TNF-α induced endothelial TF mRNA expression 
(*p<0.001 versus TNF-α alone). D. Incubation with ALA (30 μM) for 1h inhibits TNF-α 
induced transient phosphorylation of JNK, p38, and ERK. E. ALA (30 μM) inhibits 
TNF-α induced ASK1 phosphorylation  (*p<0.005 versus TNF-α alone). F. ALA (30 
μM) impairs endothelial TF promoter activation (*p<0.05 versus TNF-α alone).  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure I. ALA inhibits thrombin and collagen induced p38 
activation in platelets. 
A. ALA (30 μM) abrogates thrombin induced p38 phosphorylation (*p<0.01 versus 
thrombin alone). B. ALA inhibits collagen induced p38 phosphorylation (*p<0.01 
versus collagen alone). 
 
 
Supplement Material 
 
Material and methods 
ALA diet and carotid artery thrombosis model  
8-week-old male C57BL/6 mice weighing on average 24 g were fed a 0.21% 
w/w cholesterol diet containing either a high ALA (7.3% w/w , D06080702, Research 
Diets, New Brunswick, NJ, USA) or low ALA concentration (0.03% w/w, D06080701, 
Research Diets) for 2 weeks (supplemental table 1). ALA was supplemented as 
flaxseed oil in the high ALA group and replaced by cocoa butter in the control group. 
Thrombus formation was induced by photochemical injury on the 14th day of diet. 
Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (87 
mg/kg; Butler, Columbus, OH). Rose bengal (Fisher Scientific, Fair Lawn, NJ, USA) 
was diluted in phosphate-buffered saline (PBS) and then injected into the tail vein at 
a final concentration of 50 mg/kg. The right common carotid artery was exposed 
following a midline cervical incision and the blood flow monitored using a Doppler 
flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY) connected to a flowmeter 
(Model T106, Transonic Systems). Photochemical injury was induced by a 1.5 mW 
green light laser (540 nm; Melles Griot, Carlsbad, CA) 6 minutes after intravenous 
rose bengal injection. From the onset of injury, blood flow was monitored until 
occlusion occurred, which was defined as a flow below 0.1 ml/min for at least 1 
minute. Where mentioned, an inhibitory mouse anti-TF antibody obtained by 
immunization of rabbits against the extracellular murine TF amino acid domain 29-
250 (American Diagnostica Inc., Stamford, CA, No. 4515,) was injected intravenously 
at a concentration of 3 mg/kg body weight 20 minutes prior to the rose bengal 
injection. 
 
Immunohistochemistry 
 Occluded carotid arteries were harvested, fixed in 3% formalin and embedded 
in paraffin. Sections were stained for platelets (anti–mouse CD41; Abcam, 
Cambridge, UK; 1:50 dilution), fibrin (Anti-human, fibrin Fragment E, Cedarlane, 
Burlington, ON, Canada; 1:100 dilution) and TF (American Diagnostica; 1:50 dilution). 
Slides were blocked with 10% goat serum, and the primary antibody applied 
overnight at 4°C. Immunodetection was performed using biotinylated rabbit anti–
mouse (for fibrin and TF, 1:200 dilution), or Texas red conjugated goat anti-rat 
secondary antibodies (1:200 dilution). Slides were counterstained with hematoxylin 
and eosin (TF and fibrin) or 4',6-diamidino-2-phenylindole (CD41) . 
 
Platelet preparation 
For analysis of p38 expression, citrated whole blood was centrifuged at 170xg 
for 7 minutes to obtain platelet-rich plasma (PRP). PRP was centrifuged a second 
time at 170xg for 7 minutes to remove residual erythrocytes. To isolate platelets PRP 
was centrifuged at 350xg. Pelleted platelets were resuspended in tyrode buffer (10 
mM Hepes, 12 mM NaHCO3,137 mM NaCl, 2.7 mM KCl, 5 mM glucose; pH 7.4) and 
incubated with thrombin or collagen in the presence of ALA (30 μM) or the vehicle for 
various time points. Reactions were stopped by addition of ice-cold lysis buffer and 
p38 phosphorylation assessed by western blot analysis as described below. 
 
Platelet count and aggregation 
Platelets were counted by flow cytometry using whole blood collected in EDTA 
tubes (B&D Diagnostics, Franklin Lakes, NJ, USA). Platelet aggregation was studied 
using a Chrono-Log whole blood impedance aggregometer (Chrono-Log, Havertown, 
PA, USA). For studies performed in murine platelets, citrated blood was drawn by 
puncture from the right ventricle. For studies in human platelets, blood was obtained 
from healthy human volunteers and treated with ALA (30 μM; Cayman Chemical, Ann 
Arbor, MI, USA) or vehicle (ethanol 0.1%, Sigma Aldrich, St. Louis, USA) for 30 
minutes. Aggregation studies were performed with citrated blood within 1 hour. 
Platelets were equilibrated under constant stirring for 1 minute prior addition of 
human thrombin (0.5 U/mL; Sigma Aldrich) or equine collagen type 1 (5 μg/mL; 
Chrono-Log). Aggregation was displayed as a function of time (AGGRO/LINK® 
Software; Chrono-Log). Results were monitored for 6 minutes and expressed as 
maximal aggregation (ohm[Ω]), area under the curve (Ωxmin), and lag time 
(seconds).  
 
Fatty acid profile in aortic tissue 
Aortic tissue was pooled (n=7 per group) and FA profiles of the tissues were 
analyzed by gas chromatography. Fat was extracted via hexane:isopropanol (3:2) 
and triglycerides were saponified using methanolic sodium hydroxide. FA were 
converted to fatty acid methyl ester (FAME) with methanolic boron trifluoride. FAME 
were separated using a gas chromatograph (Hewlett Packard HP 6890 Series, GC 
Systems, Waldbronn, Germany) equipped with a 200 mm x 0,25 mm CP7421-
column (Varian, Middleburg, NL). For FAME identification, a FAME mixture was used 
as external standard (Supelco 37 component FAME mix). The proportion of different 
FAME was calculated using the ratio of the peak area of the respective FAME to the 
sum of total FAME peak areas. FA were evaluated using the HP ChemStation 
software (Hewlett Packard, CA, USA). Measurements were performed in duplicate 
and the mean value displayed.  
 
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) 
Plasma was isolated from citrated blood (3.2%; 1/10) by centrifugation (2500xg; 
4°C; 15 minutes). PT and aPTT were assessed using the START 4 analyzer 
(Diagnostica Stago, France). 
 
Thrombin generation 
Plasma thrombin generation was monitored by automated calibrated 
thrombography.1 Platelet poor plasma was mixed with human recombinant TF (5 pM) 
and a fluorogenic substrate for thrombin (Z-Gly-Gly-Arg-AMC Bachem Basle, 
Switzerland) and then recalcified. Thrombin generation was measured in a 
Fluoroskan® Ascent reader (Thermo Labsystems, Helsinki, Finland) and calculated 
using the Thrombinoscope software (Thrombinoscope BV, Maastricht, The 
Netherlands). Endogenous thrombin potential, representing the area under the 
thrombin generation curve and time to peak thrombin formation (TTP) were displayed 
using the Prism 4 software package (GraphPad Software Inc., La Jolla, USA). 
 
Cell culture 
Human aortic vascular smooth muscle cells (VSMC; Clonetics, Allschwil, 
Switzerland) and human aortic endothelial cells (HAEC; Clonetics) were cultured as 
described.2 For experiments, VSMC were serum-starved for 24 hours before 
pretreatment with ALA (Cayman Chemical, Ann Arbor, MI, USA), stearic acid (SA, 
Sigma Aldrich), linoleic acid (LA, Sigma Aldrich) or vehicle (ethanol 0.1%, Sigma 
Aldrich) for 6 or 24 hours. To block the mitogen-activated protein (MAP) kinase p38 
MAP kinase (p38), VSMC were treated with SB203580 (Sigma Aldrich; 10) for 24 
hours. For experiments with HAEC, cells were incubated with ALA for 1 hour prior 
stimulation with 5 ng/mL TNF-α (R&D Systems, Minneapolis, MN) for 4 hours for 
protein expression analysis and for 2h for analysis of TF mRNA expression. NFκB 
activation was inhibited by ammonium pyrrolidinedithiocarbamate (PDTC) or BAY 11-
7082 (both from Sigma Aldrich) pretreatment for 24 hours. To determine cytotoxicity, 
a colorimetric assay for detection of lactate dehydrogenase release was applied 
(Roche, Basel, Switzerland).  
 
Western blot 
Protein expressionin was determined by Western blot analysis. Antibodies 
against human TF (No. 4503) and tissue factor pathway inhibitor (TFPI, No. 4901) 
(both from American Diagnostica, Stamford, CT) were used at 1:2500 dilution. 
Antibodies against phosphorylated p38, ERK, JNK, and ASK1 (all from Cell 
Signaling) were used at 1:1000, 1:5000, 1:2000, and 1:2000 dilution, respectively. 
Antibodies against total p38, ERK, JNK, and ASK1 (all from Cell Signaling, Danvers, 
MA) were used at 1:2000, 1:5000, 1:2000, and 1:2000 dilution, respectively. Blots 
were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression (1:10000 dilution, Chemicon International, Temecula, CA).  
 
Factor Xa generation 
To assess TF activity factor Xa generation on the surface of VSMC and HAEC 
was analyzed using a colorimetric assay (American Diagnostica Inc, ACTICHROME). 
TF/FVIIa complex converted human factor X to factor Xa, which was measured by its 
ability to metabolize a chromogenic substrate. The absorbance of the reaction 
mixture was measured at 405 nm and values displayed after substraction of the 
background value. To confirm TF dependency of factor Xa generation in VSMC, cells 
were incubated with an inhibitory anti-TF antibody (American Diagnostica, No. 4509; 
1:200) 30 minutes prior addition of exogenous factor VIIa.  
For analysis of factor Xa generation in mouse carotid arteries, occluded right 
carotid arteries from treated and control mice were homogenized in 50 μL lysis buffer 
(0.1% Triton-X, 100 mmol Nacl, 50 mmol Tris-Hcl, pH 7.4). 25 μg of tissue lysates 
were used for measurements. TF dependency of factor Xa generation in tissue 
lysates was confirmed by incubation with an inhibitory mouse anti-TF antibody 
(American Diagnostica; No. 4515; 10 mg/ml) 30 minutes prior addition of exogenous 
factor VIIa. 
 
Real Time PCR 
RNA was extracted from VSMC, HAEC and mouse aorta using TRIzol 
Reagent (Invitrogen, Carlsbad, CA) and reverse transcribed using Ready-To-Go 
You-Prime First-Strand Beads (Amersham, Buckinghamshire, UK). For real-time 
PCR analysis the following primers were used: for full length human TF (F3): sense 
5’-TCCCCAGAGTTCACACCTTACC–3’, antisense 5’–
CCTTTCTCCTGGCCCATACAC–3’; for human ribosomal L28: sense 5’-
GCATCTGCAATGGATGGT-3’, antisense 5′-TGTTCTTGCGGATCATGTGT-3′; for 
murine full length tissue factor: sense: 5'-CAATGAATTCTCGATTGATGTGG-3', 
antisense: 5'-GGAGGATGATAAAGATGGTGGC-3'; for murine tissue factor pathway 
inhibitor: sense: 5'-ACTGTGTGTCTGTTGCTTAGCC-3', antisense: 5'-
GTTCTCGTTCCCTTCACATCCC3'; and for murine ribosomal S12: sense: 5'-
GAAGCTGCCAAAGCCTTAGA-3', antisense: 5'-AACTGCAACC-AACCACCTTC-3'. 
The amplification program consisted of 1 cycle at 95°C for 10 minutes followed by 35 
cycles with a denaturing phase at 95°C for 30 seconds, an annealing phase at 60°C 
for 1 minute, and an elongation phase at 72° for 1 minute. Melting curve analysis 
confirmed the accuracy of the amplicon, and PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel. In each real-time PCR run for human TF 
and L28, a standard curve generated from serial dilutions of purified amplicons was 
included. For murine TF and S12 the ΔΔCt threshold cycle method was used. 
 
Nuclear Extracts and NFκB activity  
For measurement of NFkB activity, VSMC were treated with ALA (30 μM)  or 
the vehicle for 24 hours. Nuclear extracts were obtained from VSMC or mouse aorta 
using a nuclear extraction kit (Active Motif, Carlsbad, USA). Total protein (20 µg) was 
loaded in each well, and NFκB activity was measured using a TransAM NFκB p65 kit 
(Active Motif). 
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